Finepoint Capital LP Avidity Biosciences, Inc. Transaction History
Finepoint Capital LP
- $1.18 Billion
- Q4 2024
A detailed history of Finepoint Capital LP transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Finepoint Capital LP holds 391,300 shares of RNA stock, worth $12.9 Million. This represents 0.96% of its overall portfolio holdings.
Number of Shares
391,300Holding current value
$12.9 Million% of portfolio
0.96%Shares
1 transactions
Others Institutions Holding RNA
# of Institutions
252Shares Held
110MCall Options Held
197KPut Options Held
184K-
Price T Rowe Associates Inc Baltimore, MD11MShares$365 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.43MShares$311 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$285 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.11MShares$268 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY7.93MShares$262 Million3.76% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.72B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...